These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 16030028)

  • 1. Primary chemotherapy with gemcitabine as prolonged infusion, non-pegylated liposomal doxorubicin and docetaxel in patients with early breast cancer: final results of a phase II trial.
    Schmid P; Krocker J; Jehn C; Michniewicz K; Lehenbauer-Dehm S; Eggemann H; Heilmann V; Kümmel S; Schulz CO; Dieing A; Wischnewsky MB; Hauptmann S; Elling D; Possinger K; Flath B
    Ann Oncol; 2005 Oct; 16(10):1624-31. PubMed ID: 16030028
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Primary chemotherapy with gemcitabine, liposomal doxorubicin and docetaxel in patients with locally advanced breast cancer: results of a phase I trial.
    Schmid P; Krocker J; Schulz CO; Michniewicz K; Dieing A; Eggemann H; Heilmann V; Blohmer JU; Sezer O; Elling D; Possinger K
    Anticancer Drugs; 2005 Jan; 16(1):21-9. PubMed ID: 15613900
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of advanced breast cancer with docetaxel and gemcitabine with and without human granulocyte colony-stimulating factor.
    Kornek GV; Haider K; Kwasny W; Raderer M; Schüll B; Payrits T; Depisch D; Kovats E; Lang F; Scheithauer W
    Clin Cancer Res; 2002 May; 8(5):1051-6. PubMed ID: 12006518
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gemcitabine as prolonged infusion and vinorelbine in anthracycline and/or taxane pretreated metastatic breast cancer: a phase II study.
    Schmid P; Heilmann V; Schulz CO; Dieing A; Lehenbauer-Dehm S; Jehn C; Sezer O; Possinger K; Flath B
    J Cancer Res Clin Oncol; 2005 Sep; 131(9):568-74. PubMed ID: 16044345
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Second-line neoadjuvant vinorelbine and gemcitabine combination in locally advanced breast cancer showing no early response to TAC.
    Halim A; Wahba H
    Med Oncol; 2012 Jun; 29(2):454-8. PubMed ID: 21350875
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biweekly docetaxel and gemcitabine as neoadjuvant chemotherapy in stage II and III breast cancer patients: preliminary results of a phase II and pharmacogenomic study.
    Estévez LG; Sánchez-Rovira P; Dómine M; León A; Calvo I; Jaén A; Casado V; Rubio G; Daz M; Miró C; Lobo F
    Semin Oncol; 2004 Apr; 31(2 Suppl 5):31-6. PubMed ID: 15199530
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gemcitabine plus docetaxel administered every other week as first-line treatment of metastatic breast cancer: preliminary results from a phase II trial.
    Pelegrí A; Calvo L; Mayordomo JI; Florián J; Vázquez S; Arcusa A; Martn-Richard M; Bayo JL; Virizuela J; Carrasco E; Antón A;
    Semin Oncol; 2004 Apr; 31(2 Suppl 5):20-4. PubMed ID: 15199528
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bevacizumab added to neoadjuvant chemotherapy for breast cancer.
    Bear HD; Tang G; Rastogi P; Geyer CE; Robidoux A; Atkins JN; Baez-Diaz L; Brufsky AM; Mehta RS; Fehrenbacher L; Young JA; Senecal FM; Gaur R; Margolese RG; Adams PT; Gross HM; Costantino JP; Swain SM; Mamounas EP; Wolmark N
    N Engl J Med; 2012 Jan; 366(4):310-20. PubMed ID: 22276821
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II study of pegylated liposomal doxorubicin in combination with gemcitabine in patients with metastatic breast cancer.
    Rivera E; Valero V; Arun B; Royce M; Adinin R; Hoelzer K; Walters R; Wade JL; Pusztai L; Hortobagyi GN
    J Clin Oncol; 2003 Sep; 21(17):3249-54. PubMed ID: 12947059
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II study of neoadjuvant docetaxel/ vinorelbine followed by surgery and adjuvant doxorubicin/cyclophosphamide in women with stage II/III breast cancer.
    Limentani SA; Brufsky AM; Erban JK; Jahanzeb M; Lewis D
    Clin Breast Cancer; 2006 Feb; 6(6):511-7. PubMed ID: 16595034
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II study of gemcitabine, doxorubicin and paclitaxel (GAT) as first-line chemotherapy for metastatic breast cancer: a translational research experience.
    Passardi A; Massa I; Zoli W; Gianni L; Milandri C; Zumaglini F; Nanni O; Maltoni R; Frassineti GL; Amadori D
    BMC Cancer; 2006 Mar; 6():76. PubMed ID: 16551351
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of the liposomal anthracyclines and other systemic therapies in the management of advanced breast cancer.
    Robert NJ; Vogel CL; Henderson IC; Sparano JA; Moore MR; Silverman P; Overmoyer BA; Shapiro CL; Park JW; Colbern GT; Winer EP; Gabizon AA
    Semin Oncol; 2004 Dec; 31(6 Suppl 13):106-46. PubMed ID: 15717740
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biweekly docetaxel and gemcitabine as neoadjuvant chemotherapy followed by adjuvant doxorubicin and cyclophosphamide therapy in stage II and III breast cancer patients: results of a phase II study.
    Estévez LG; Sánchez-Rovira P; Dómine M; León A; Calvo I; Jaén A; Casado V; Rubio G; Díaz M; Miró C; Lobo F; Carrasco E; Casillas M; San Antonio B
    Clin Transl Oncol; 2007 May; 9(5):317-22. PubMed ID: 17525042
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II study of neoadjuvant gemcitabine, pegylated liposomal doxorubicin, and docetaxel in locally advanced breast cancer.
    Artioli G; Mocellin S; Borgato L; Cappetta A; Bozza F; Zavagno G; Zovato S; Marchet A; Pastorelli D
    Anticancer Res; 2010 Sep; 30(9):3817-21. PubMed ID: 20944176
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase I and pharmacokinetic study of docetaxel combined with Doxil (pegylated liposomal doxorubicin) without and with granulocyte colony stimulating factor.
    Pavlick AC; Chodkiewicz C; Liebes L; Hamilton A; Wasserheit C; Hochster H; Speyer J; Phillips Z; Downey A; Sorich J; Muggia F
    Anticancer Drugs; 2004 Feb; 15(2):119-25. PubMed ID: 15075667
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I trial of pegylated liposomal doxorubicin and docetaxel in advanced breast cancer.
    Sparano JA; Malik U; Rajdev L; Sarta C; Hopkins U; Wolff AC
    J Clin Oncol; 2001 Jun; 19(12):3117-25. PubMed ID: 11408509
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Monthly docetaxel and weekly gemcitabine in metastatic breast cancer: a phase II trial.
    Laufman LR; Spiridonidis CH; Pritchard J; Roach R; Zangmeister J; Larrimer N; Moore T; Segal M; Jones J; Patel T; Gutterman L; Carman L; Colborn D; Kuebler JP
    Ann Oncol; 2001 Sep; 12(9):1259-64. PubMed ID: 11697837
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trial.
    Hensley ML; Maki R; Venkatraman E; Geller G; Lovegren M; Aghajanian C; Sabbatini P; Tong W; Barakat R; Spriggs DR
    J Clin Oncol; 2002 Jun; 20(12):2824-31. PubMed ID: 12065559
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dose-dense primary systemic chemotherapy with gemcitabine plus epirubicin sequentially followed by docetaxel for early breast cancer: final results of a phase I/II trial.
    Schneeweiss A; Schuetz F; Rudlowski C; Hahn M; Lauschner I; Sinn HP; von Fournier D; Sohn C
    Anticancer Drugs; 2005 Oct; 16(9):1023-8. PubMed ID: 16162980
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II study of pegylated liposomal doxorubicin (Caelyx) and docetaxel as first-line treatment in metastatic breast cancer.
    Alexopoulos A; Karamouzis MV; Stavrinides H; Ardavanis A; Kandilis K; Stavrakakis J; Georganta C; Rigatos G
    Ann Oncol; 2004 Jun; 15(6):891-5. PubMed ID: 15151945
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.